PT96028A - Processo para a preparacao de um sistema terapeutico transdermico contendo 17-(ciclopropil-metil)-alfa-(1,1-dimetil-etil)-4,5-epoxi-18,19-di-hidro-3-hidroxi-6-metoxi-alfa-metil-6,14-etenomorfinano-7-metanol(buprenorfinal) como ingrediente activo - Google Patents

Processo para a preparacao de um sistema terapeutico transdermico contendo 17-(ciclopropil-metil)-alfa-(1,1-dimetil-etil)-4,5-epoxi-18,19-di-hidro-3-hidroxi-6-metoxi-alfa-metil-6,14-etenomorfinano-7-metanol(buprenorfinal) como ingrediente activo

Info

Publication number
PT96028A
PT96028A PT96028A PT9602890A PT96028A PT 96028 A PT96028 A PT 96028A PT 96028 A PT96028 A PT 96028A PT 9602890 A PT9602890 A PT 9602890A PT 96028 A PT96028 A PT 96028A
Authority
PT
Portugal
Prior art keywords
methyl
etenomorfinane
buprenorfinal
alfa
cyclopropyl
Prior art date
Application number
PT96028A
Other languages
English (en)
Other versions
PT96028B (pt
Inventor
Thomas Hille
Lothar Deurer
Hans-Rainer Hoffmann
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6394373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT96028(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of PT96028A publication Critical patent/PT96028A/pt
Publication of PT96028B publication Critical patent/PT96028B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT96028A 1989-11-29 1990-11-28 Processo para a preparacao de um sistema terapeutico transdermico contendo 17-(ciclopropil-metil)-alfa-(1,1-dimetil-etil)-4,5-epoxi-18,19-di-hidro-3-hidroxi-6-metoxi-alfa-metil-6,14-etenomorfinano-7-metanol(buprenorfinal) como ingrediente activo PT96028B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3939376A DE3939376C1 (pt) 1989-11-29 1989-11-29

Publications (2)

Publication Number Publication Date
PT96028A true PT96028A (pt) 1991-09-13
PT96028B PT96028B (pt) 1998-02-27

Family

ID=6394373

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96028A PT96028B (pt) 1989-11-29 1990-11-28 Processo para a preparacao de um sistema terapeutico transdermico contendo 17-(ciclopropil-metil)-alfa-(1,1-dimetil-etil)-4,5-epoxi-18,19-di-hidro-3-hidroxi-6-metoxi-alfa-metil-6,14-etenomorfinano-7-metanol(buprenorfinal) como ingrediente activo

Country Status (25)

Country Link
EP (1) EP0430019B1 (pt)
JP (1) JPH0818984B2 (pt)
KR (1) KR950015061B1 (pt)
AT (1) ATE135205T1 (pt)
AU (1) AU632182B2 (pt)
CA (1) CA2030178C (pt)
CZ (1) CZ282557B6 (pt)
DE (2) DE3939376C1 (pt)
DK (1) DK0430019T3 (pt)
ES (1) ES2086353T3 (pt)
FI (1) FI100379B (pt)
GR (1) GR3020177T3 (pt)
HR (1) HRP930675B1 (pt)
HU (1) HU206266B (pt)
IE (1) IE73247B1 (pt)
IL (1) IL96243A (pt)
MY (1) MY105347A (pt)
NO (1) NO303107B1 (pt)
NZ (1) NZ236191A (pt)
PL (1) PL165396B1 (pt)
PT (1) PT96028B (pt)
SI (1) SI9012260B (pt)
SK (1) SK279687B6 (pt)
YU (1) YU47956B (pt)
ZA (1) ZA909544B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
DE19705138A1 (de) 1997-02-11 1998-08-13 Lohmann Therapie Syst Lts Dehnbares transdermales therapeutisches System
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE19850517B4 (de) 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
DE19901085C2 (de) * 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
DE10056012A1 (de) * 2000-11-11 2002-05-16 Beiersdorf Ag Flexible Barrierefolie für ein Trägermaterial für medizinische Zwecke
DE10056014A1 (de) * 2000-11-11 2002-05-16 Beiersdorf Ag Mehrschichtige Trägerkonstruktion für wirkstofhaltige Pflastersyteme
JP4194277B2 (ja) 2002-01-25 2008-12-10 久光製薬株式会社 架橋ポリマーを主成分とする粘着性成形体の製造方法
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
EP1526848B1 (de) * 2002-08-09 2007-07-18 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
CN1829482B (zh) * 2003-07-25 2012-10-10 欧洲凯尔特公司 治疗依赖戒断的药盒
DE102004009903A1 (de) 2004-02-26 2005-09-22 Grünenthal GmbH Pflaster mit reduzierter Hautirritation
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
DE102006057083A1 (de) 2005-12-05 2007-06-28 Lg Electronics Inc. Beleuchtungsvorrichtung für einen Kühlschrank
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN103200944B (zh) 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
AP4036A (en) 2011-12-12 2017-02-22 Lohmann Therapie Syst Lts Transdermal delivery system comprising buprenorphine
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
HUE031662T2 (en) 2013-06-04 2017-07-28 Lts Lohmann Therapie Systeme Ag Transdermal drug delivery system
DE102014013448A1 (de) * 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
CN109045341A (zh) * 2018-05-07 2018-12-21 武汉兴嘉业堂医疗科技发展有限公司 一种活血止痛压敏胶及其制备方法、应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
JPS60123417A (ja) * 1983-12-07 1985-07-02 Nitto Electric Ind Co Ltd 薬物投与部材
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
JPS632533A (ja) * 1986-06-23 1988-01-07 Yamakawa Sangyo Kk 精密鋳造用鋳物砂
CH672888A5 (pt) * 1986-11-07 1990-01-15 Mepha Ag
DE3862405D1 (de) * 1987-03-09 1991-05-23 Alza Corp Zusammensetzung zur vorbeugung einer kontaktallergie durch gleichzeitiges verabreichen eines kortikosteroids mit einem sensiblisierenden arzneistoff.
EP0375689B1 (en) * 1987-06-01 1992-08-12 Warner-Lambert Company A pharmaceutical composition adapted for transdermal delivery of an opoid drug.
DE3843237A1 (de) * 1988-12-22 1990-07-05 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit einem antiadipositum als aktivem bestandteil

Also Published As

Publication number Publication date
EP0430019A2 (de) 1991-06-05
JPH03193732A (ja) 1991-08-23
CS9005598A2 (en) 1991-12-17
AU632182B2 (en) 1992-12-17
NO905103D0 (no) 1990-11-26
NZ236191A (en) 1993-05-26
FI905892A (fi) 1991-05-30
DE59010192D1 (de) 1996-04-18
GR3020177T3 (en) 1996-09-30
IL96243A (en) 1994-11-28
FI905892A0 (fi) 1990-11-29
CA2030178A1 (en) 1991-05-30
HUT55643A (en) 1991-06-28
SI9012260B (sl) 1998-06-30
KR910009249A (ko) 1991-06-28
DE3939376C1 (pt) 1991-05-08
MY105347A (en) 1994-09-30
AU6569990A (en) 1991-06-06
SK279687B6 (sk) 1999-02-11
NO905103L (no) 1991-05-30
SI9012260A (en) 1997-10-31
IL96243A0 (en) 1991-08-16
YU47956B (sh) 1996-07-24
HRP930675A2 (en) 1994-10-31
FI100379B (fi) 1997-11-28
EP0430019B1 (de) 1996-03-13
ZA909544B (en) 1992-08-26
ATE135205T1 (de) 1996-03-15
PL287989A1 (en) 1991-09-09
CA2030178C (en) 1995-08-15
CZ282557B6 (cs) 1997-08-13
EP0430019A3 (en) 1991-09-18
ES2086353T3 (es) 1996-07-01
HRP930675B1 (en) 1999-10-31
DK0430019T3 (da) 1996-07-22
PL165396B1 (en) 1994-12-30
NO303107B1 (no) 1998-06-02
JPH0818984B2 (ja) 1996-02-28
HU206266B (en) 1992-10-28
KR950015061B1 (ko) 1995-12-21
IE904290A1 (en) 1991-06-05
PT96028B (pt) 1998-02-27
IE73247B1 (en) 1997-05-21
YU226090A (sh) 1992-12-21

Similar Documents

Publication Publication Date Title
PT96028A (pt) Processo para a preparacao de um sistema terapeutico transdermico contendo 17-(ciclopropil-metil)-alfa-(1,1-dimetil-etil)-4,5-epoxi-18,19-di-hidro-3-hidroxi-6-metoxi-alfa-metil-6,14-etenomorfinano-7-metanol(buprenorfinal) como ingrediente activo
CA2153572A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
AU637637B2 (en) Estrogen-containing active substance plaster
ES2057080T3 (es) Sistema terapeutico transdermal empleando fisostigmina como componente activo, asi como procedimiento para su preparacion.
PT81751B (pt) Processo para a preparacao de adesivos para aplicacao de medicamentos por via transdermica
CA2338859A1 (en) Estradiol-containing patch for transdermal administration of hormones
PT92650A (pt) Processo para a preparacao de um sistema terapeutico transdermico contendo norpseudoefedrina como ingrediente activo
ES2105334T3 (es) Sistema terapeutico percutaneo para la administracion de fisostigmina en la piel y el procedimiento para su obtencion.
ATE64539T1 (de) Dermale und transdermale therapeutische systeme mit musterfoermig aufgetragener klebschicht, sowie verfahren zur dessen herstellung.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910410

FG3A Patent granted, date of granting

Effective date: 19971106

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20121106